Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

Celia Camacho-Toledano, Isabel Machín-Díaz, Leticia Calahorra, María Cabañas-Cotillas, David Otaegui, Tamara Castillo-Triviño, Luisa María Villar, Lucienne Costa-Frossard, Manuel Comabella, Luciana Midaglia, José Manuel García-Domínguez, Jennifer García-Arocha, María Cristina Ortega and Diego Clemente

Abstract

Background: The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine. Fingolimod is a disease-modifying treatment that belongs to the sphingosine-1-phosphate receptor modulators. In addition to inhibiting T cell egress from lymph nodes, fingolimod promotes the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs), whose monocytic subset (M-MDSCs) can be used as a biomarker of disease severity, as well as the degree of demyelination and extent of axonal damage in the experimental autoimmune encephalomyelitis (EAE) model of MS. In the present study, we have assessed whether the abundance of circulating M-MDSCs may represent a useful biomarker of fingolimod efficacy in EAE and in the clinical context of MS patients.

Methods: Treatment with vehicle or fingolimod was orally administered to EAE mice for 14 days in an individualized manner, starting the day when each mouse began to develop clinical signs. Peripheral blood from EAE mice was collected previous to treatment and human peripheral blood mononuclear cells (PBMCs) were collected from fingolimod to treat MS patients' peripheral blood. In both cases, M-MDSCs abundance was analyzed by flow cytometry and its relationship with the future clinical affection of each individual animal or patient was assessed.

Results: Fingolimod-treated animals presented a milder EAE course with less demyelination and axonal damage, although a few animals did not respond well to treatment and they invariably had fewer M-MDSCs prior to initiating the treatment. Remarkably, M-MDSC abundance was also found to be an important and specific parameter to distinguish EAE mice prone to better fingolimod efficacy. Finally, in a translational effort, M-MDSCs were quantified in MS patients at baseline and correlated with different clinical parameters after 12 months of fingolimod treatment. M-MDSCs at baseline were highly representative of a good therapeutic response to fingolimod, i.e., patients who met at least two of the criteria used to define non-evidence of disease activity-3 (NEDA-3) 12 months after treatment.

Conclusion: Our data indicate that M-MDSCs might be a useful predictive biomarker of the response of MS patients to fingolimod.

Keywords: EAE, MDSCs, S1PR, Responder and non-responder, Personalized medicine

Background

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) that affects about 2.8 million people worldwide [1]. However,
the development of MS does not follow a unique pattern but rather it has an unpredictable course. Around 85% of patients develop the relapsing–remitting (RR-MS) form of the disease, which is essentially characterized by episodes of neurological dysfunction (relapses) followed by partial or full recovery [2]. Our current understanding of the influence of the immune system on MS pathology has led to the approval of 17 disease-modifying treatments (DMTs) for RR-MS, providing neurologists and patients a wide range of therapeutic options [3]. Clinicians must select treatment strategies for each individual based on a personalized risk and benefit assessment [4]. However, while the therapeutic options are constantly evolving, escalation is still a common strategy followed in the decision-making process for MS treatment [5]. It consists in using a first-line low risk, moderate efficacy therapy, and then monitoring the effectiveness of the treatment. When the DMT fails in controlling the disease activity, it is switched to a more efficacious one. This approach is quite conservative and it is most applicable to patients with a lower risk of developing an aggressive form of MS [6]. Mounting evidence indicates that early implementation of efficacious treatment may prevent chronic immune activation and better preserve long-term neural integrity [7]. Indeed, the most effective drugs should be indicated in patients with very active MS associated with an earlier development of disability. Among other DMTs, those designed to act as sphingosine-1-phosphate receptor (S1PR) modulators are a large family of drugs that has the ability to be used for this purpose.

Fingolimod (FTY720), known commercially as Gilenya™, is an S1PR antagonist that was the first oral DMT approved for the treatment of RR-MS [8]. It is a structural analogue of sphingosine that upon phosphorylation acts as a modulator of S1PR1, 3, 4 and 5, with higher affinity for S1PR1. Fingolimod is a potent inhibitor of lymphocyte egression from lymphoid tissues as a result of the internalization and degradation of S1PR1 [9], although additional biological effects on other CNS or immune cells have also been described [10]. The heterogeneity of MS makes it difficult and costly to determine the effectiveness of any specific treatment, including fingolimod. Hence, it is important to identify biomarkers that provide information about disease progression and treatment efficacy for each individual to avoid undesirable side effects, and to reduce the cost burden to Health Systems. In this sense, a number of biomarkers have been described to monitor the effects of exposure to a drug and its pharmacodynamics, as well as to identify the likelihood of toxicity as an adverse effect of fingolimod treatment [11–13]. In recent years, the role of cells of the adaptive immune response as predictive biomarkers to anticipate the most positive response to fingolimod in MS patients has most positive response to fingolimod in MS patients has been addressed [14–16]. However, there is little data regarding the innate immune cells to predict the responsiveness of MS patients to fingolimod, attributed to CD56bright NK cells [17], with no data regarding the myeloid cell compartment.

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population generated in the bone marrow during myelopoiesis that contribute to the innate immune response. Under pathological conditions, blocking their differentiation in conjunction with exposure to inflammatory mediators activates these cells, provoking their acquisition of immunosuppressive functions [18, 19]. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, splenic MDSCs are composed of two subpopulations: polymorphonuclear-MDSCs (PMN-MDSCs, CD11b+Ly-6CintLy-6G+) and monocytic-MDSCs (M-MDSCs, CD11b+Ly-6C+Ly-6G−), which are phenotypically indistinguishable from Ly-6Chi inflammatory monocytes in blood, i.e., Ly-6C′ cells [20]). The abundance of M-MDSCs has repeatedly been related to disease severity in the EAE model [21–24]. Indeed, in several immune-mediated animal models other than EAE, it appears that fingolimod or other S1PR agonists may be implicated in the infiltration capacity, the expansion and the immunosuppressive activity of MDSCs through their antagonism of S1PR1, 3 and 5 [25–28]. Hence, there appears to be a clear relationship between the therapeutic response to fingolimod and the abundance of MDSCs. However, the utility of these cells as potential biomarkers of the response to fingolimod in inflammatory conditions (including EAE and MS) remains totally unexplored. Circulating PMN-MDSCs (identified as CD11b+CD33+HLA-DR−/lowCD14+CD15+LOX1+ cells) and M-MDSCs (CD11b+CD33+HLA-DR−/lowCD14+CD15− cells) [29], yet MDSCs have been little studied in MS and there is conflicting data as to the cell type most strongly involved or altered during the clinical course of MS [30–32]. There is also little information on the possible effect of DMTs on MDSCs, most of which has been limited to glatiramer acetate (GA), which has been reported to induce a negligible increase in MDSCs [32]. Notably, there is no data about MDSCs as a predictive biomarker for MS treatments.

In the current work, we present novel data in the context of EAE and MS patients indicating that M-MDSCs could serve as a biomarker for responsiveness to fingolimod treatment and its efficacy in EAE. Patients who exhibited a good therapeutic response to fingolimod at 12 months of treatment had a greater level of circulating M-MDSCs at baseline relative to those considered to be non-responders. Our observations in EAE and MS might serve to identify new tools that in turn, could help...
modify the prescribing criteria of neurologists’ and ultimately, patients’ quality of life.

**Methods**

**Induction of EAE**

Chronic progressive EAE was induced by subcutaneous immunization of female 6- to 8-week-old C57BL/6 mice (Janvier Labs, France) with 200 µL of a Myelin Oligodendrocyte Glycoprotein solution (200 µg, MOG35-55 peptide: Genscript, New Jersey, USA) emulsified in complete Freund’s Adjuvant (CFA) that contained 4 mg/mL of *Mycobacterium tuberculosis* (BD Biosciences, Franklin Lakes, New Jersey, USA). Immunized mice were administered Pertussis toxin intravenously (iv) through the tail vein (250 ng/mouse: Sigma-Aldrich, St. Louis, MO, USA) in a final volume of 100 µL on the day of immunization and 48 h later. EAE was scored clinically on a daily basis by three observers in a double-blind manner as follows: 0, no detectable signs of EAE; 0.5, half limp tail; 1, whole limp tail; 1.5, hind limb inhibition (unsteady gait and/or poor hind leg grip); 2, hind limb weakness; 2.5, bilateral partial hind limb paralysis or unilateral full hind limb paralysis; 3, complete bilateral hind limb paralysis (paraplegia); 3.5, partial forelimb paralysis; 4, tetraplegia; 4.5, moribund; and 5, death. In accordance with ethical regulations, humane end-point criteria were applied when an animal reached a clinical score ≥ 4, when clinical score ≥ 3 was reached for more than 48 h, or when self-mutilation was evident, persistent retention of urine, or more than 48 h, even if the EAE score was <3. The generation of sounds, lordokyphosis or stereotypic behavior were considered as signs of stress. In the present study, no animals presented signs of pain or stress, and none reached a clinical score >3.5.

The individualized treatment and follow-up was carried out as follows. The 1st day clinical signs of EAE were detected (“onset,” therapeutic window during which the clinical score debuts between 0.5 and 1.5), each animal was administered fingolimod orally (N=18; 3 mg/kg in distilled water: EAE-FTY720, kindly provided by Novartis Pharma AG, Switzerland [33–35]) or the vehicle alone (N = 19; distilled water: EAE-Veh) on a daily basis for 14 days. All mice were killed on the 15th day post-onset (dpo) and four different variables were analyzed in all the EAE mice: (a) the clinical signs; (b) the peripheral blood content; (c) splenic content; and (d) histopathological parameters.

All the animal manipulations were approved by the institutional ethical committee (Comité Ético de Experimentación Animal del Hospital Nacional de Parapléjicos), and all the experiments were performed in compliance with the European guidelines for animal research (EC Council Directive 2010/63/EU, 90/219/EEC, Regulation No. 1946/2003), and with the Spanish National and Regional Guidelines for Animal Experimentation (RD 53/2013 and 178/2004, Ley 32/2007 and 9/2003, Decreto 320/2010).

**Evaluation of the clinical signs**

The clinical signs were established through observational evaluation of the functional behavior of each mouse, allowing different parameters of the EAE clinical course to be defined: (i) the day of onset, the 1st day mice had a clinical score ≥ 0.5; (ii) clinical score at onset; (iii) the maximum clinical score; (iv) the day when animals reached the maximum clinical score or “peak” defined as the 1st day a clinical score ≥ 1.5 was repeated; (v) the severity index, the maximum clinical score/the days elapsed from onset to peak [24]; (vi) the accumulated clinical score from onset to peak and the total accumulated clinical score, considered as the sum of the individual clinical scores from the day of onset until the peak or the end of the treatment, respectively; (vii) the percentage recovery [(the maximum clinical score − the residual score at the end of treatment) × 100/maximum clinical score]; (viii) the recovery index [(the maximum clinical score at peak − the residual score at the end of treatment)/days elapsed from the peak to the recovery]; and (ix) the residual score, the clinical score at the end of the follow-up.

**Flow cytometry analysis of peripheral blood and splenocytes**

Blood was obtained from the retro-orbital venous sinus of isoflurane-anesthetized mice at disease onset and collected in 2% EDTA tubes, and the erythrocytes were then lysed in a 15-mL tube with 2.5 mL ACK lysis buffer: 8.29 g/L NH₄Cl; 1 g/L KHCO₃; 1 mM EDTA in distilled H₂O at pH 7.4 (Panreac). Subsequently, the lysis reaction was stopped by adding wash buffer (sterile 1 × Phosphate Buffered Saline—PBS) and the blood cells were recovered by centrifugation at 210 g for 5 min at room temperature (RT). The Fc cell receptors were then blocked for 10 min at 4 °C with an anti-CD16/CD32 antibody (10 µg/mL: BD Biosciences 553142) and the cells were resuspended in 25 µL of staining buffer: PBS supplemented with 10% heat-inactivated fetal bovine serum (FBS: Linus); 25 mM HEPES buffer (Gibco); and 2% Penicillin/Streptomycin (P/S: Gibco). The cells were further labeled for 20 min at 4 °C in the dark with the following fluorochrome-conjugated monoclonal antibodies diluted in 25 µL of staining buffer (Additional file 1: Table S1): anti-Ly-6C-FITC (AL-21 clone), anti-Ly-6G-PE (1A8 clone), anti-CD11b-PerCP-Cy5.5 (M1/70 clone: all from BD Biosciences); anti-MHC-II-PE-Cy7 (M5/114.15.2 clone), anti-MHC-II-PE-Cy7 (M5/114.15.2 clone),
areas appeared yellowish-white. Finally, the slides were myelinated areas were stained blue and demyelinated after rinsing with abundant tap water, correct differentiation was assessed under the microscope to ensure myelinated areas were stained blue and demyelinated areas appeared yellowish-white. Finally, the slides were dehydrated in a graded ethanol series and xylol solutions, and they were mounted with Entellan (Merck) for preservation.

To analyze axonal damage, the non-phosphorylated form of the neurofilament protein (SMI-32) was stained by immunohistochemistry. After several rinses in PB, the sections were treared with 10% methanol in PB for 20 min and then incubated for 1 h at RT in incubation buffer: 5% normal donkey serum (NDS: Merck) and 0.2% Triton X-100 (Merck) diluted in PBS. Immunostaining was performed by incubating the sections overnight at 4 °C with the SMI-32 primary antibody (Biolegend: Additional file 1: Table S1) in incubation buffer. The sections were then incubated for 1 h at RT with the corresponding fluorescent secondary antibody diluted in staining buffer (1:1000: Invitrogen), the cell nuclei were stained with Hoechst (10 µg/mL: Sigma-Aldrich) and the samples were mounted in Fluoromount-G (Southern Biotech). Omission of the primary antibody as a control staining yielded no signal.

Image acquisition and analysis
To quantify the degree of demyelination, sections were selected randomly from the sub-cohort group of 18 EAE mice (at least three sections per mouse, each separated by 340 µm). EC stained spinal cord sections were analyzed on a stereological Olympus BX61 microscope to quantify demyelination, using a DP71 camera (Olympus) and VisionPharm software for anatomical mapping. Superimages were acquired at a ×10 magnification using the mosaic tool and analyzed with ImageJ, expressing the results as the total area of white matter demyelination and relative to the whole white matter area.

To quantify axonal damage, ×20 tile scan images from the spinal cord of each animal were obtained on an IX83 inverted microscope (Olympus) equipped with CellSense Dimensions software for large-area imaging. The area of axon damage relative to the whole spinal cord or the total demyelinated area was analyzed with an ad hoc algorithm designed by the Microscopy and Image Analysis Core Facility at the Hospital Nacional de Parapléjicos. After selecting the demyelinated area, a threshold for immunofluorescence was established and SMI-32 immunostaining was measured, representing the result as the percentage of axonal damage within the inflammatory lesion.

MS patient cohort for M-MDSC blood analysis
31 RR-MS patients fulfilling the 2010-revised McDonald diagnostic criteria [36] who initiated fingolimod treatment were recruited at the Vall d’Hebron Hospital (Barcelona), the Ramón y Cajal Hospital (Madrid) or the Donostia Hospital (San Sebastián). The study was...
approved by the corresponding local ethics committees, and informed written consent was obtained from all the participants in accordance with the Helsinki declaration. None of the MS patients in this study received cortico-steroids in the last 30 days and they were treated with fingolimod (0.5 mg/day) based on current guidelines. In patients who switched treatment from a prior DMT, a minimum washout period of 24 h was established for those who had been receiving interferon-beta (IFN-β) or GA, of 2 months for natalizumab, and of 1 month for azathioprine. All the patients completed 12 months of fingolimod treatment (for demographic and clinical characteristics see Additional file 2: Table S2).

Neurological evaluation was carried out at baseline, 6 and 12 months after initiation of the fingolimod therapy with additional evaluation in case of relapses. Relapses were defined as a worsening of neurological impairment or the appearance of new symptoms attributable to MS in the absence of fever or infection, lasting at least 24 h and preceded by at least 1 month of stability [37]. A standardized brain magnetic resonance imaging (MRI) protocol (axial T2, axial T2 FLAIR and T1) was implemented to reliably detect T2 lesions at baseline and new or enlarging lesions at 12 months after initiation of the fingolimod therapy. The transverse T1-weighted sequence was systematically repeated after gadolinium (Gd) injection (0.2 mmol/kg) whenever T2 lesions were demonstrated. Both MRI scans were performed using the same 1.5-T equipment with a slice thickness varying from 2 to 5 mm. Disability was assessed by a trained neurologists using the Kurtzke Expanded Disability Status Scale (EDSS) [38] prior to the initiation of fingolimod therapy and then at 6 and 12 months, and whole blood was collected from these patients at the same time points during follow-up.

Flow cytometry analysis of peripheral blood cells from fingolimod-treated patients

Fresh anti-coagulated EDTA blood was obtained by venipuncture the same day of the treatment, before the first dose of fingolimod and after 12 months of treatment. Human peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation (GE-171440-02, Merck), collected from the interphase, washed with isolation buffer (2.23 g/L d-glucose, 2.2 g/L sodium citrate, 0.8 g/L citric acid, 0.5% Bovine Serum Albumin in PBS) and further centrifuged at 350 g for 10 min at RT. The cell pellet was resuspended in FBS, counted and aliquoted 1:1 in FBS with 20% dimethylsulfoxide (DMSO: Sigma-Aldrich). The samples were then stored long-term in liquid nitrogen at −170 °C until use.

Freshly thawed PBMCs (1 × 10^6) were washed twice with PBS and stained with Zombie NIR Dye (Biolegend) following the manufacturer’s instructions. After 15 min at RT in the dark, the cells were washed with PBS and recovered at 390 g for 5 min. PBMCs were then resuspended in 25 µL of staining buffer and incubated for 10 min at 4 °C with Beriglobin (50 µg/mL: CSL Behring) to block the Fc receptors. Subsequently, 25 µL of the antibody mix diluted in staining buffer was added to the cells for 30 min at 4 °C in the dark. The antibody panel (Additional file 1: Table S1) to stain M-MDSCs included anti-CD15-FITC (HI98 clone), anti-CD14-PerCP-Cy5.5 (Mφ29 clone), anti-CD11b-PE-Cy7 (ICRF44 clone), anti-CD33-APC (WM53 clone) and anti-HLA-DR-BV421 (G46-6 clone: BD Biosciences). After staining, the PBMCs were rinsed with staining buffer at 390 g for 5 min at RT, resuspended in 0.1% PFA diluted in PBS and stored at 4 °C in the dark until the next day. The samples were then analyzed in a FACS Canto II cytometer (BD Biosciences) with the corresponding controls and 100,000 events were recorded in the mononuclear cell (MNC) gate. Compensation controls were obtained by incubating each single antibody with the anti-mouse Ig,k/Negative Control Compensation Particle Set (CompBeads, BD Biosciences). Fluorescence Minus One controls were set-up in pooled samples to avoid any variation between the experimental conditions and the data were analyzed with FlowJo v.10.6.2 software (FlowJo, LLC-BD Biosciences).

Statistical analysis

The data were analyzed with SigmaPlot version 11.0 (SYS
tat Software Inc.). Age, and gender balance were compared using a Fisher exact test. A Student’s t-test was used to compare pairs of the different groups of mice/patients with parametric distributions or a Mann–Whitney U test was used for non-parametric distributions. A Spearman test was carried out for the correlation analyses. A ROC curve analysis was performed to determine the discriminative ability of the different clinical parameters scored and to determine the threshold of M-MDSCs, with the highest sensitivity and specificity to separate responder from non-responder mice. In addition, treatment efficacy was also determined by a ROC curve analysis. Finally, a Cox regression analysis was performed to determine the probability of reaching the population median of the clinical parameters presented by the vehicles as a function of different categorical and non-categorical variables. The minimum statistical significance was set at p < 0.05: *p < 0.05, **p < 0.01, ***p < 0.001.

Results

Individualized fingolimod treatment accelerates disease recovery in EAE

Fingolimod has been seen previously to improve the clinical course of EAE [39, 40], although in all these
earlier studies fingolimod treatment was carried out on randomly assigned groups of mice with diverse clinical scores, without taking into account the disease severity of each individual animal. In order to better approximate to the clinical situation of MS patients, we used an individualized treatment protocol that started at the specific point of disease onset for each animal. Differences between the experimental groups were observed from 1 dpo onwards. In general terms, the individualized fingolimod treatment significantly reduced the maximum clinical score of each animal, enhancing their recovery at a higher and faster rate (the percentage recovery and recovery index, respectively). In addition, a decrease in their residual score and reduced total accumulated score was observed relative to the EAE-Veh animals (Fig. 1A, Table 1). The amelioration in the clinical signs observed in mice administered fingolimod was paralleled by a reduction in demyelination: demyelinated area- EAE-Vehicle: 59,796.97 ± 22,444.54, EAE-FTY720: 22,168.25 ± 15,461.25, p = 0.043); % of the demyelinated area within the white matter (EAE-Veh: 6.26 ± 2.30, EAE-FTY720: 2.14 ± 1.44, p = 0.042: Fig. 1B, C, F); and % of axonal damage within the demyelinated area (EAE-Veh: 0.98 ± 0.22, EAE-FTY720: 0.43 ± 0.12, p = 0.045: Fig. 1D, E, G). Moreover, the individualized fingolimod treatment also dampened the abundance of splenic CD3+CD8+ and CD3+CD25+ T lymphocytes (Table 1).

In summary, the individualized follow-up in each mouse from the point of disease onset appeared to be a good strategy to explore the differential efficacy of fingolimod treatment in EAE.

The abundance of Ly-6C\textsuperscript{hi} cells in peripheral blood is related to a milder long-term EAE course in fingolimod-administered mice

To establish the M-MDSC values that might predict a future response to fingolimod in MS, we explored the relationship between their abundance in the blood and the future short and long-term clinical course in fingolimod-administered EAE mice. Highly immunosuppressive M-MDSCs in the spleen and spinal cord of EAE mice, as well as circulating M-MDSCs, are phenotypically indistinguishable from CD11b\textsuperscript{+}Ly-6C\textsuperscript{hi}Ly-6G\textsuperscript{−\textlow} inflammatory monocytes, also called Ly-6C\textsuperscript{hi} cells [18, 20, 21, 41, 42]. Interestingly, high levels of splenic Ly-6C\textsuperscript{hi} cells at the peak of EAE have been directly associated with a milder disease course [24, 43]. Hence, to explore whether M-MDSCs could be used as a predictive tool for fingolimod-induced reduction in the severity of the clinical course of EAE, we first investigated the correlation between the abundance of Ly-6C\textsuperscript{hi} cells in the peripheral blood at disease onset and different short- and long-term clinical parameters of the clinical course of EAE. As in the case of EAE-Veh, the higher proportion of Ly-6C\textsuperscript{hi} cells relative to the total blood content was directly related to a milder EAE disease course: lower maximum score at peak, lower total accumulated and residual clinical scores, and stronger relative disease recovery in EAE-FTY720 mice (Fig. 2A–D). These data pointed to the quantification of Ly-6C\textsuperscript{hi} cells as an interesting parameter in the search for biomarkers that link disease severity reduction after fingolimod treatment.

To check whether the initial randomized distribution of EAE mice influenced the long-term effects of fingolimod, we compared the clinical and immunological baseline conditions between the two experimental groups. The day of onset and the clinical score at that point did not differ between these groups: day at onset (EAE-Veh: 13 dpi Inter Quartile Range—IQR 12–14), EAE-FTY720: 13 dpi IQR 12–13, p = 0.789); and clinical score at onset (EAE-Veh: 0.75 IQR 0.50–0.75), EAE-FTY720: 0.75 IQR 0.5–1.0, p = 0.763). Importantly, no major differences were reported in the abundance of Ly-6C\textsuperscript{hi} cells between the animals treated with vehicle or fingolimod, neither relative to the total number of blood cells or in the myeloid subset (Fig. 3A, B). Moreover, the Ly-6C\textsuperscript{hi} cells from both animal groups showed a similar mean fluorescence intensity (MFI) in terms of their activation or the differentiation markers expressed prior to vehicle or fingolimod administration (Fig. 3C–E). Therefore, these data clearly indicated that the content and characteristics of the circulating Ly-6C\textsuperscript{hi} cells was not biased between the two groups of animals prior to treatment.

We also looked for differences in the abundance of circulating T cells, the main targets for both fingolimod and MDSCs, prior to vehicle/fingolimod administration. No differences were detected in CD3\textsuperscript{+} or CD8\textsuperscript{+} T lymphocytes, although there was a slightly higher percentage of CD4\textsuperscript{+} T lymphocytes in animals that then received...
Fig. 1  (See legend on previous page.)
fingolimod (Table 2). To check whether the difference in CD4+ T lymphocytes might reflect an imbalance in the immunological environment, we compared the Ly-6Chi/T lymphocyte ratio between the two experimental groups. No differences were detected in the relative abundance of Ly-6Chi cells and CD3+, CD4+ or CD8+ T lymphocytes between mice administered fingolimod or the vehicle alone, downplaying the significance of the differences at baseline after considering the inflammatory microenvironment as a whole. These results clearly showed that the therapeutic effect of fingolimod observed is not related to a clinical or immunological bias associated with the individualized treatment of EAE.

Circulating Ly-6C hi cells represent an excellent biomarker to predict the responsiveness to fingolimod in EAE mice

Although fingolimod was therapeutically effective in most of the EAE-FTY720 mice (responder mice), 3 of the 18 mice showed a clinical course indistinguishable from the control EAE-Veh mice, i.e., non-responders (Fig. 4A–C). To quantify this effect, we considered non-responder mice as those with a similar or worse clinical level than the median of the EAE-Veh group. Thus, EAE-FTY720 non-responders were defined as those with a maximum clinical score ≥ 3, with a clinical recovery score ≤ 25%, a recovery of the clinical score between the peak and the end of the follow-up ≤ 0.5 and a residual clinical score ≥ 2.25. Following this distribution, EAE-FTY720 responder mice exhibited a significantly milder disease course than EAE-Veh or EAE-FTY720 non-responders, which in turn showed no difference between them (Table 3). Indeed, similarities between EAE-Vehicle mice and EAE-FTY720 non-responders were also observed in the splenic immunological status at the end of the follow-up. Interestingly, only responder mice had a significantly smaller proportion of splenic CD3+, CD4+, CD8+ and CD3+CD25+ T lymphocytes (Table 3).

When the level of circulating Ly-6C hi cells in the blood prior to fingolimod administration was analyzed, EAE-FTY720 non-responders had a remarkable lower abundance of these cells within the whole blood cells than EAE-FTY720 responders prior to treatment initiation (Fig. 4D, E). Importantly, Ly-6C hi cell levels had excellent discriminatory power to assess the risk of being responder or non-responder based on the median value of the maximum peak clinical score, the percentage recovery of the clinical score and the residual clinical score (AUC 0.956, 95% C.I.—confidence interval 0.853–1.058; p < 0.05). In all cases, we established 2.75% of Ly-6C hi cells within the whole leukocyte population at disease onset as the cut-off value indicative of a future therapeutic responsiveness in EAE mice (100% specificity, 95% C.I. 29.24–100%; 86.67% sensitivity, 95% C.I. 59.54–98.34%; Fig. 5A, B). By contrast, the mere abundance of this cell type was not able to discriminate between responder and non-responder EAE-FTY720 mice based on the median accumulated clinical score at the end of the experiment (AUC 0.875, 95% CI 0.703–1.047; p = 0.092) B (AUC 0.667, 95% CI 0.305–1.028; p = 0.374; Fig. 5C–F).

Table 1 Comparison of the clinical parameters and splenic T cell populations in EAE mice following individualized treatment with fingolimod or vehicle

| Clinical parameters | Vehicle | FTY720 | p value |
|---------------------|---------|--------|---------|
| Maximum score       | 3 (2.25–3) | 2.38 (1.18–2.75) | <0.05 |
| dpi peak            | 15 (14–17) | 15 (14–15.25) | ns      |
| Severity index      | 0.75 (0.50–1.00) | 0.625 (0.33–0.75) | ns      |
| Peak accumulated score | 6.50 (5.63–9.00) | 5.69 (3.68–6.81) | ns      |
| Total accumulated score | 37.25 (23.00–42.38) | 18.88 (12.59–27.16) | <0.01 |
| % Recovery          | 25.00 (12.50–33.30) | 72.73 (53.41–80.24) | <0.01 |
| Recovery index      | 0.093 (0.04–0.17) | 0.16 (0.10–0.21) | <0.05 |
| Residual score      | 2.25 (1.00–2.63) | 0.50 (0.50–0.88) | <0.01 |
| Spleen              |         |        |         |
| % CD3+ /Total blood cells | 15.15 ± 0.97 | 11.06 ± 0.93 | <0.01 |
| % CD4+ /Total blood cells | 9.11 ± 0.64 | 7.75 ± 0.63 | ns      |
| % CD8+ /Total blood cells | 4.98 ± 0.36 | 2.79 ± 0.28 | <0.001 |
| % CD3+CD25+ /Total blood cells | 1.32 ± 0.08 | 1.09 ± 0.07 | <0.05 |
| % CD3+CD69+ /Total blood cells | 1.77 ± 0.12 | 1.86 ± 0.10 | ns      |

The data are expressed as the median (IQR) for the clinical parameters and the mean ± SEM for the splenic parameters. The results of applying a Student’s t-test or a non-parametric Mann–Whitney test are shown: dpi day post-immunization; IQR interquartile range; ns non-significant.
In summary, our data clearly indicated that circulating Ly-6C<sup>hi</sup> cell content at the onset of EAE is an extraordinary tool to determine future therapeutic responsiveness of EAE mice to fingolimod treatment in terms of the maximum affectation, the extent of recovery and the residual score achieved by each individual animal.

Circulating Ly-6C<sup>hi</sup> cells constitute a good biomarker of fingolimod treatment efficacy in EAE

As in clinical practice, examination of EAE responder mice yielded high variability in the efficacy demonstrated by fingolimod treatment in each individual mouse. In fact, our data revealed that the higher the number of circulating Ly-6C<sup>hi</sup> cells prior to treatment, the greater...
Fig. 3 (See legend on previous page.)
the difference in the maximum score achieved by EAE-FTY720 mice relative to the median score of the EAE-Veh mice (Fig. 6A). Hence, Ly-6C\textsuperscript{hi} cells may be a putative biomarker not only of responsiveness to fingolimod treatment, but also to the individual degree of drug efficacy.

To assess this phenomenon, we classified the effect of fingolimod in each EAE mouse as high or low based on the median of the EAE-FTY720 group as a whole. Fingolimod treatment was considered to be high efficacy when an EAE-FTY720 mouse had a maximum clinical score < 2.5, a total accumulated clinical score < 19, clinical recovery > 72.73%, a recovery index > 0.16 or a residual clinical score < 1.0. The abundance of Ly-6C\textsuperscript{hi} cells prior to fingolimod treatment could not discriminate between animals prone to present high/low treatment

### Table 2 Immunological cells in the blood of EAE mice at disease onset

|                   | Vehicle | FTY720 | p value |
|-------------------|---------|--------|---------|
| % CD3\textsuperscript{+}/Total blood cells | 12.94 ± 1.32 | 16.77 ± 1.63 | ns |
| % CD4\textsuperscript{+}/Total blood cells | 8.09 ± 0.77 | 10.91 ± 1.03 | < 0.05 |
| % CD8\textsuperscript{+}/Total blood cells | 3.32 ± 0.30 | 4.42 ± 0.51 | ns |
| % Ly-6C\textsuperscript{hi}/Total blood cells: % CD3\textsuperscript{+} | 0.47 ± 0.13 | 0.39 ± 0.10 | ns |
| % Ly-6C\textsuperscript{hi}/Total blood cells: % CD4\textsuperscript{+} | 0.72 ± 0.19 | 0.58 ± 0.15 | ns |
| % Ly-6C\textsuperscript{hi}/Total blood cells: % CD8\textsuperscript{+} | 1.83 ± 0.55 | 1.68 ± 0.50 | ns |
| % Ly-6C\textsuperscript{hi}/Myeloid cells: % CD3\textsuperscript{+} | 0.58 ± 0.16 | 0.50 ± 0.13 | ns |
| % Ly-6C\textsuperscript{hi}/Myeloid cells: % CD4\textsuperscript{+} | 0.89 ± 0.23 | 0.75 ± 0.18 | ns |
| % Ly-6C\textsuperscript{hi}/Myeloid cells: % CD8\textsuperscript{+} | 2.25 ± 0.65 | 2.15 ± 0.62 | ns |

The data are expressed as the mean ± SEM. The result of the Student's t-test or a non-parametric Mann–Whitney test is shown: ns not significant.

**Fig. 4** Circulating levels of Ly-6C\textsuperscript{hi} cells are higher in fingolimod responder EAE mice. A–C Graphic representation of the clinical course of one representative EAE-Veh (A Ly-6C\textsuperscript{hi} cells/total blood cells = 2.26% or Ly-6C\textsuperscript{hi} cells/myeloid cells = 3.15%), one non-responder (B Ly-6C\textsuperscript{hi} cells/total blood cells = 2.32%; Ly-6C\textsuperscript{hi} cells/myeloid cells = 3.20%) and one responder EAE-FTY720 mouse (C Ly-6C\textsuperscript{hi} cells/total blood cells = 4.81% or Ly-6C\textsuperscript{hi} cells/myeloid cells = 6.02%). EAE-Veh animals developed a severe clinical course indistinguishable from non-responder EAE-FTY720 mice. D, E Responder EAE-FTY720 mice (N = 3) had a much higher abundance of circulating Ly-6C\textsuperscript{hi} cells among the total blood cells (D) or the myeloid component (E) than non-responder EAE-FTY720 mice (N = 15) prior to initiating treatment.
efficacy based on the median of the maximum clinical score (AUC 0.765, 95% CI 0.524–1.007; $p = 0.058$), the % recovery of the clinical score (AUC 0.700, 95% CI 0.450–0.950; $p = 0.155$), or the recovery index (AUC 0.741, 95% CI 0.491–0.990; $p = 0.085$). Interestingly, Ly-6C$^+$ cell level was seen to be an important parameter to distinguish EAE mice in which fingolimod acts with high efficacy based on the median value of the total accumulated clinical score (Fig. 6B) and of the residual score at the end of fingolimod administration (Fig. 6D). In fact, having more than 5.15% (100% specificity, 99% C.I. 55.50–100%; 66.67% sensitivity, 99% C.I. 21.91–95.84%; Fig. 6C) or 4.59% (100% specificity, 95% C.I. 26.59–100%; 57.14% sensitivity, 95% C.I. 22.34–87.33%; Fig. 6E) of circulating Ly-6C$^+$ cells at disease onset were valid cut-off points in EAE mice to distinguish those prone to experience high efficacy of fingolimod treatment in terms of the total accumulated clinical score or residual score, respectively.

In summary, the proportion of peripheral blood Ly-6C$^+$ cells at disease onset appeared to be a good biomarker of fingolimod efficacy, whereby the higher the level of these cells the less severe the disease after fingolimod treatment.

### Table 3
Comparison of the clinical parameters and splenic T cell populations in EAE-Vehicle, and EAE-FTY720 responder and non-responder mice

| Clinical parameters                  | EAE-Vehicle | EAE-FTY720 | $p$ value |
|--------------------------------------|-------------|------------|-----------|
| Maximum score                        | 3 (2.25–3)  | 3 (3–3)    | 2.25*     | <0.01 |
| dpi peak                             | 15 (14–17)  | 15 (13–15) | 15 (14–16)| ns    |
| Severity index                       | 0.75 (0.50–1) | 0.75 (0.60–1) | 0.63 (0.33–0.69) | ns |
| Peak accumulated score               | 6.5 (5.63–9) | 7 (6.50–9.75) | 4.5*     | <0.005 |
| Total accumulated score              | 37.25 (23–45.38) | 41.38 (34.38–45.50) | 18*     | <0.0001 |
| % Recovery                           | 25 (12.5–33.30) | 8.33 (0–25) | 75*     | <0.001 |
| Recovery index                       | 0.09 (0.04–0.17) | 0.04 (0–0.09) | 0.17*     | <0.01 |
| Residual score                       | 2.25 (1–2.63) | 2.75 (2.25–3) | 0.5* | <0.001 |

| Spleen                               |               |            |           |
|--------------------------------------|---------------|------------|-----------|
| % CD$^+$ /total blood cells           | 15.15 ± 0.97  | 15.68 ± 3.27 | 10.13 ± 0.77* | <0.01 |
| % CD4$^+$ /total blood cells          | 9.11 ± 0.64   | 10.51 ± 2.17 | 7.20 ± 0.56* | <0.05 |
| % CD8$^+$ /total blood cells          | 4.98 ± 0.36   | 4.47 ± 0.91 | 2.46 ± 0.21* | <0.0001 |
| % CD3 CD25$^+$ /total blood cells     | 1.32 ± 0.08   | 1.33 ± 0.25 | 1.04 ± 0.07* | <0.05 |
| % CD3 CD69$^+$ /total blood cells     | 1.77 ± 0.12   | 2.24 ± 0.31 | 1.78 ± 0.10 | ns |

The data are expressed as the median (IQR). One-way ANOVA or a non-parametric ANOVA on ranks tests are shown: dpi day post-immunization; ns not significant; IQR interquartile range

*Represents significantly different groups

The responsiveness and efficacy to fingolimod treatment in EAE is exclusively influenced by the level of circulating Ly-6C$^+$ cells

The existence of differences in the responsiveness and efficacy to fingolimod could be the result of the sum of different clinical and immunological factors other than Ly-6C$^+$ cell levels. To test this hypothesis, we performed a Cox proportional hazard regression analysis to determine the likelihood of EAE mice achieving a maximum clinical score $\geq 3$ (median of the EAE-Veh mice, i.e., paraplegia) or a residual score <2 as a function of the following variables found at disease onset: dpi; clinical score; the abundance of Ly-6C$^+$ cells; CD3$^+$, CD4$^+$, CD8$^+$ T cells; the ratios between Ly-6C$^+$ cells/lymphocyte subsets, and some other myeloid cell subsets, such as neutrophils (CD11b$^+$Ly-6C$^{int}$Ly-6G$^{hi}$) or dendritic cells (CD11b$^+$CD11c$^+$); and the experimental animal group, i.e., treated or not with fingolimod. Importantly, Ly-6C$^+$ cell abundance at disease onset and the absence of fingolimod treatment were the only two variables associated with a lower risk of reaching paraplegia or completing the treatment with a residual clinical score <2 ($p < 0.05$).
Fig. 5 Ly-6Chi cell content is an excellent biomarker to predict responsiveness to fingolimod in EAE mice. A ROC curve analysis showing that Ly-6CChi cell content presented the highest discriminatory ability for responder and non-responder EAE mice classified using the median of maximum clinical score, the % recovery or the residual score. B Cut-off value for the Ly-6CChi cells/total blood cells to predict good responsiveness to fingolimod. C–F The level of Ly-6CChi cells could not discriminate between responder and non-responder EAE-FTY720 mice based on the median of the total accumulated clinical score (C, D) or the recovery index (E, F). AUC area under the curve (N = 18 mice).
Fig. 6 Ly-6Chi cells are a good biomarker for the efficacy of fingolimod treatment in EAE. A The higher the Ly-6Chi cell content at onset, the greater the difference in the maximum score reached by EAE-FTY720 mice compared to the median of the EAE-Veh group. B, D ROC curve analysis showing that Ly-6Chi cells had a good capacity to discriminate high efficacy as opposed to low efficacy EAE mice through the median accumulated clinical score (B) and the residual score (D). C, E Cut-off values for the Ly-6Chi cells/total blood cells to predict those EAE mice that will present a higher total accumulated or a lower residual score than the median of EAE-FTY720 mice at the end of the experimental evaluation.
in both cases). A high abundance of Ly-6C<sup>hi</sup> cells at disease onset was a clear protective factor (HR 0.0949, 95% C.I. 0.0106–0.851) while the absence of fingolimod treatment was a prominent risk factor for reaching paraplegia (HR 11.195, 95% C.I. 1.212–103.397). On the other hand, a high abundance of Ly-6C<sup>hi</sup> cells at disease onset increased the likelihood of completing the treatment with little clinical sequelae (HR 1.894, 95% C.I. 1.238–2.898), whereas not being treated with fingolimod prevented such an outcome (HR 0.149, 95% C.I. 0.0358–0.623). All these data clearly indicate that the abundance of Ly-6C<sup>hi</sup> cells is a good and specific biomarker for fingolimod treatment efficacy in the EAE model.

**M-MDSC abundance is independent of the fingolimod to treat MS patients' characteristics at baseline**

To establish a parallel with the observations in the EAE mouse model, we carried out a translational study in 31 MS patients (demographic data are shown in Additional file 2: Table S2) to assess whether circulating M-MDSC abundance at baseline may be related to the future response of MS patients to fingolimod. We first assessed whether the M-MDSC content of the mononuclear cell fraction (M-MDSCs/MNCs) at baseline was independent of the patients’ age (r = 0.0649, p = 0.726), EDSS (r = −0.102, p = 0.584), or number of Gd<sup>+</sup> enhancing lesions (r = 0.199, p = 0.279). Switching treatment from natalizumab (Ntz) to fingolimod has been associated with a risk of MS reactivation [44–46]. In order to avoid misinterpretation of the M-MDSC abundance due to the presence of patients with a very active immune response, we discriminated patients who switched treatment from Ntz (Ntz-patients, N = 11) from those who were naïve or who had previously received another first-line treatment (Non-Ntz patients, N = 20). Interestingly, the level of M-MDSCs was similar between NON-Ntz and Ntz patients (Non-Ntz 1.23 ± 0.30, Ntz 1.22 ± 0.66; p = 0.397). In fact, the M-MDSCs in both Ntz and Non-Ntz patients remained independent of the baseline parameters: age (Non-Ntz r = −0.125, p = 0.594; Ntz r = 0.397, p = 0.210); EDSS (Non-Ntz r = −0.144, p = 0.538; Ntz r = 0.0961, p = 0.755), number of Gd<sup>+</sup> enhancing lesions (Non-Ntz r = 0.179, p = 0.444; Ntz r = 0.100, p = 0.755). Therefore, our data indicated that M-MDSC abundance at baseline was very clearly independent of demographics at and switching from Ntz treatment.

**M-MDSC abundance at baseline is greater in fingolimod responder patients**

To establish whether the abundance of M-MDSCs might be related to the future response to fingolimod at 12 months, the baseline M-MDSC level was correlated to the different criteria considered to define non-evidence of disease activity (NEDA-3), i.e., no new relapses; absence of confirmed disability progression (CDP), understood as 1 point increase in the EDSS for patients with a basal EDSS ≤ 5 (1.5 points when baseline EDSS was 0) or of 0.5 points in patients with basal EDSS > 5; and no increase in brain MRI activity [a composite measure of any new T2 and/or gadolinium-enhancing lesions (Gd+ lesions)] relative to the baseline MRI [14]. After 12 months of treatment, 74.19% of patients had not experienced relapses, with a significantly lower annual relapse rate (ARR) than the year before starting fingolimod treatment (1.10 ± 0.18 vs 0.32 ± 0.11; p < 0.001). Despite the fact that 77.42% of patients maintained or decreased their EDSS after treatment, no significant differences were observed in the EDSS score before and after fingolimod treatment [3.0 (2.0–4.0) vs 2.5 (2.0–4.0); p = 0.603]. Finally, the proportion of patients with no new T2 lesions after 12 months of fingolimod treatment was 61.29%, whereas 87.10% of patients did not present new Gd<sup>+</sup> lesions after 12 months of follow-up. However, M-MDSC abundance at baseline was not related to the future clinical course at 12 months after treatment (Additional file 3: Table S3).

To address the ability of M-MDSCs to discriminate between MS patients who will respond distinctly to fingolimod, “responder” MS patients were considered as those who met all the NEDA-3 criteria (R-MS<sub>NEDA-3</sub>), whereas “non-responder” MS patients were those who met two or less NEDA-3 criteria at the end of the follow-up period (NR-MS<sub>NEDA-3</sub>). Accordingly, 13 of the 31 patients (41.94%) were considered as R-MS<sub>NEDA-3</sub>. No relationship was found between the abundance of M-MDSCs and the different clinical parameters found after 12 months follow-up in R-MS<sub>NEDA-3</sub> (Additional file 3: Table S3) and hence, the percentage of M-MDSCs at baseline was not significantly different between the R-MS<sub>NEDA-3</sub> and NR-MS<sub>NEDA-3</sub> subgroups (R-MS<sub>NEDA-3</sub> 1.54 ± 0.56, NR-MS<sub>NEDA-3</sub> 1.01 ± 0.32; p = 0.447).

In a second approximation, we restricted the concept of “responder” MS patients to those the so-called clinical response (R-MS<sub>CR</sub>), i.e., MS patients with no new relapses and no CDP after 12 months of treatment [47, 48]. In this sense, 20 of the 31 patients (64.52%) were considered as R-MS<sub>CR</sub>. Again, no relationship was found between the abundance of M-MDSCs and the different clinical parameters found after 12 months follow-up in R-MS<sub>CR</sub> (Additional file 3: Table S3). Moreover, the percentage of M-MDSCs at baseline was not significantly different between the R-MS<sub>CR</sub> and NR-MS<sub>CR</sub> subgroups (R-MS<sub>CR</sub> 1.44 ± 0.39, NR-MS<sub>CR</sub> 0.85 ± 0.45; p = 0.094).
In a next step, we restricted the concept of “responder” MS patients (R-MS) to those showing any good therapeutic response (GTR), i.e., MS patients who meet 2 or more of the NEDA-3 criteria after 12 months of treatment [14, 15]. Accordingly, “non-responder” MS patients (NR-MS) were those who met one or none NEDA-3 criteria. In this sense, 25 out of 31 patients (80.61%) were classified as R-MS. Again, no relationship was established between the abundance of M-MDSCs and the clinical parameters after a 12-month follow-up within the R-MS group (Additional file 3: Table S3). Importantly, R-MS patients did have a significantly higher percentage of M-MDSCs than NR-MS (R-MS 1.48 ± 0.35, NR-MS 0.16 ± 0.06; p < 0.05; Fig. 7A, B). As such, the abundance of M-MDSCs did appear to be a useful tool to identify MS patients with a suboptimal therapeutic response to fingolimod.

Finally, we assessed whether the level of M-MDSCs differed between R-MS and NR-MS for each of the clinical criteria used in the definition of NEDA-3. M-MDSCs were unable to distinguish R-MS and NR-MS patients based on the absence of new relapses or new MRI activity: relapses—R-MS 1.26 ± 0.35, NR-MS 1.14 ± 0.60 (p = 0.701); MRI activity—R-MS 1.50 ± 0.45, NR-MS 0.80 ± 0.29 (p = 0.441: Fig. 7C, D). Importantly, the level of M-MDSCs was higher in MS patients with no evidence of an increase in disability (R-MS 1.43 ± 0.34, NR-MS 0.17 ± 0.07; p < 0.05: Fig. 7E).

In summary, these data displayed a clear parallel with the preclinical results reported previously in the EAE mice and they showed the ability of M-MDSC abundance to discriminate a good response to fingolimod treatment in MS patients. Moreover, M-MDSCs were enriched in patients whose disability remained stable or diminished after 12 months of fingolimod treatment.

Discussion
The present study demonstrates the potential of circulating Ly-6C<sup>hi</sup> cells/M-MDSCs as a biomarker of response to fingolimod in both EAE mice and MS patients, respectively. From a preclinical point of view, our results show that peripheral Ly-6C<sup>hi</sup> cell content at disease onset is the only immunological variable that allows us to distinguish the presence of a highly effective therapeutic response to fingolimod in the EAE model. M-MDSCs are also strongly represented in R-MS patients, irrespective of their demographic and baseline parameters. Furthermore, we identified that more circulating M-MDSCs are present at baseline in R-MS patients with no signs of CDP after a 12-month follow-up.

The growing list of DMTs available for the treatment of MS [49] makes the identification of predictive biomarkers for treatment response ever more necessary to help clinicians adopt optimal treatment management strategies for MS patients [5]. In this context, promising results have been obtained from preclinical experimental procedures, although the translation of these findings to the clinic is often disappointing [50, 51]. This could be due to divergences between EAE and MS, as well as the more simplified interpretation of preclinical observations [52, 53]. To facilitate the translation of new potential biomarkers discovered in a preclinical setting into the clinical environment, the approximation of the EAE treatment strategy to the clinical reality of MS should be addressed. A large number of studies aimed at evaluating the efficacy of new treatments in EAE administer the drugs to animals prophylactically [54–56]. Conversely, a large amount of preclinical therapeutic data was obtained by treating at the same time point all EAE animals once they had reached a certain clinical score, or when only 50–60% of the animals had developed clinical signs of EAE [57–59], ignoring the inter-individual biological variability in disease severity found among immunized mice [24]. This type of approach is easier to follow as all animals are treated uniformly, monitoring is unified and the experimental procedure is completed simultaneously. However, these two experimental approximations are far from close to real clinical practice. In order to more closely resemble the clinical situation, we performed individualized administration and clinical assessment of each EAE mouse, and thus, vehicle or fingolimod treatment commenced at the time that each mouse began to develop clinical signs of EAE. Our data regarding the amelioration of the clinical course, the decrease in T cells and the histopathological preservation after fingolimod treatment demonstrated that this kind of experimental approach is as therapeutically valid as other preclinical designs [60, 61]. However, it also adds some valuable information about the inter-individual heterogeneity regarding the efficacy of the

![Fig. 7 M-MDSCs are more abundant at baseline in patients with a good therapeutic response to fingolimod. A Flow cytometry strategy of analysis for M-MDSCs in human PBMC samples. In both “responder” and “non-responder” MS patients, immature myeloid cells were gated from mononuclear subpopulation as CD33<sup>+</sup>HLA-DR<sup>−</sup> populations. CD33<sup>+</sup>HLA-DR<sup>−</sup> cells were assessed for CD14 and CD15 expression to identify the M-MDSC subset defined as CD14<sup>−</sup>CD15<sup>−</sup>. B M-MDSCs were more abundant in R-MS patients (those who meet two or more criteria for NEDA-3: good therapeutic response—GTR) than NR-MS patients. C, D M-MDSCs were similar between R-MS and NR-MS patients according the absence of new relapses (C), or new T2 lesions or Gd<sup>+</sup> enhancing lesions in MRI after 12 months of treatment (D). E M-MDSCs were clearly higher in patients with stable disability 12 months after fingolimod treatment. R-MS “Responder”-MS patients; NR-MS “non-responder”-MS patients. B R-MS N = 25, NR-MS N = 6; in C R-MS N = 23, NR-MS N = 8; in D R-MS N = 19, NR-MS N = 12; in E R-MS N = 26, NR-MS N = 5.
Fig. 7 (See legend on previous page.)
molecule tested, something closer to the reality of patient management.

Our data indicate that the level of Ly-6C\textsuperscript{hi} cells is a good and specific biomarker of clinical efficacy and responsiveness to fingolimod in EAE mice, i.e., it is useful to distinguish responder mice, and those that will have a less severe clinical development and fewer sequelae, following fingolimod treatment. Ly-6C\textsuperscript{hi} cells are able to distinguish fingolimod-responsive mice on the basis of maximum clinical score, residual score, and percent recovery, but fail on the basis of cumulative score or recovery rate. This would indicate that the level of Ly-6C\textsuperscript{hi} cells is adequate to predict the effect of fingolimod associated with attenuation of early CNS changes, i.e., reduced influx of inflammatory monocytes and T cells. However, prediction of later phenomena more related to clinical recovery, where remyelination and neuroprotection are more relevant, may be confounded by the direct effects of fingolimod on CNS resident cells, such as oligodendrocytes, astrocytes or even neurons [62].

The presence of experimental bias resulting from the randomized distribution of the groups can be ruled out since the timings, the level of clinical affectation and the immunoregulatory balance between M-MDSCs/T cells were similar between both experimental groups prior to treatment. Importantly, our case study is one of the few to demonstrate that EAE is very useful to test the responsiveness and efficacy of a given DMT. Most drugs that are successful in EAE fail to translate adequately into the clinic. This is due, among other reasons, from not taking into account the bimodal distribution of behavioral responses to drugs [63]. The nomenclature of “responders” and “non-responders” has been commonly used in MS patients for some time [14, 64, 65]. However, it is anecdotic in the study of new treatments in the EAE model [66, 67]. Our individualized study represents another exception since it mirrors the natural variability that exists among animals in response to fingolimod treatment, similar to that witnessed in MS patients. Data from this kind of experimental design will help identify so-called “disease classifying biomarkers”, which distinguish the MS endophenotypes that can yield measurable predictions in terms of prognosis and response to a corresponding treatment, a phenomenon that is crucial to improve future MS trials [68].

To our knowledge, this is the first study that describes the potential of Ly-6C\textsuperscript{hi} cells as biomarkers of response to DMTs in EAE. These findings are in agreement with our earlier observations demonstrating a clear relationship between the abundance of splenic Ly-6C\textsuperscript{hi} cells and the severity of the clinical course of EAE mice [23, 24]. In addition, it was reported that clinical improvements induced in EAE or other experimental models of MS through different experimental strategies increased the number and activity of splenic and CNS infiltrated Ly-6C\textsuperscript{hi} cells [32, 43, 69–72]. The seemingly controversial inverse relationship between the abundance of Ly-6C\textsuperscript{hi} cells (i.e., inflammatory monocytes/M-MDSCs) and clinical improvement in EAE has been explained by recent experimental observations. It is currently not possible to discriminate circulating Ly-6C\textsuperscript{hi} inflammatory monocytes from M-MDSCs in mice [18, 20, 21, 41, 42]. The vast majority of studies explored Ly-6C\textsuperscript{hi} function around the peak of EAE disease, when the greatest tissue damage has already occurred and Ly-6C\textsuperscript{hi} cells had acquired immunosuppressive functions, leading to a decrease in T cell proliferation and Th1/Th17 differentiation [41]. However, the deleterious role attributed to Ly-6C\textsuperscript{hi} cells in EAE results from their study during the pro-inflammatory phase of this animal model. In fact, an increase in these cells leads to an earlier onset and a worse disease severity [73], whereas their elimination resulted in milder disease courses [74].

To interpret these studies, it is important to consider the true functional consequences of Ly-6C\textsuperscript{hi} cells as they switch from behaving as antigen presenting cells at EAE onset to becoming T cell suppressors at the peak of the EAE clinical course [41]. Importantly, some studies identified peripheral blood Ly-6C\textsuperscript{hi} cells as precursors of M-MDSCs in certain tissues. At the peak of EAE, about 50% of the anti-inflammatory Arg-I\textsuperscript{+} monocyte-derived myeloid cells in the CNS are derived from iNOS\textsuperscript{+} pro-inflammatory cells that colonize this organ at disease onset [75]. Moreover, almost 98% of the Arg-I\textsuperscript{+} anti-inflammatory phagocytes infiltrating the CNS at the peak of the clinical course are thought to be derived from Ly-6C\textsuperscript{hi}CCR2\textsuperscript{+} monocytes that invade the inflamed tissue from the onset of the disease [76]. Interestingly, it was shown that all the Arg-I\textsuperscript{+} cells present in the spinal cord at the peak of EAE have a phenotype of M-MDSCs and suppressor activity [77]. Along similar lines, the crucial role of pro-inflammatory Ly-6C\textsuperscript{hi} cells in effective repair at later stages of chronic inflammatory pathologies was reported recently [78]. All these data suggest that the vast majority of immunoregulatory phagocytic cells present in the CNS at the peak of EAE would be derived from circulating inflammatory monocytes that share their phenotype with M-MDSCs. Therefore, circulating Ly-6C\textsuperscript{hi} monocytes appear to be the only appropriate cell subset to be analyzed in order to validate M-MDSCs as a predictive tool for the response to fingolimod in EAE.

The promising preclinical results mentioned above and the need to find biomarkers that predict the response of the plethora of medications already approved to treat MS, would make M-MDSCs promising candidates to be used in clinical studies. To our knowledge, this is the first work...
that interrogates the role of M-MDSCs as predictive biomarkers of fingolimod treatment in MS. The only work that has explored the impact of DMTs on M-MDSCs indicated a non-significant increase in the number of total M-MDSCs in RR-MS patients treated with GA [32]. In fact, the scarcity of data about M-MDSCs and MS are somehow contradictory, and encourages a more in depth analysis on larger patient cohorts [31, 32]. To date, the analyses of immune cells as predictive biomarkers of the response to fingolimod centered on cells involved in adaptive immunity [14, 15], as described for Ntz [79] or IFN-β [80]. By contrast, differences in cells of the innate immune response between those MS patients who respond efficiently to fingolimod or not has been restricted to regulatory CD56bright NK cells, with a higher abundance in R-MS patients than in NR-MS patients [17]. However, the implication of myeloid cells as biomarkers of response to fingolimod has yet to be analyzed. In this sense, this study shows for the first time that the abundance of M-MDSCs at baseline is higher in MS patients that respond well to fingolimod. Moreover, the abundance of M-MDSCs in R-MS patients is mainly associated to the absence of CDP. Our results are consistent with our previous data regarding the higher abundance of circulating M-MDSCs in RR-MS patients at relapse relative to the lower EDSS at baseline and after a 1-year follow-up [81]. Therefore, EDSS seems to be the most relevant clinical parameter related to the enrichment of immunoregulatory M-MDSCs. In this regard, it has been shown that the immunosuppressive activity of M-MDSCs is impaired in patients with progressive MS [31]. Moreover, the level of splenic M-MDSCs in EAE is related to increased myelin and neuronal preservation [24, 81] and the secretome of M-MDSCs in EAE has the ability to promote proliferation, survival and differentiation of oligodendrocyte precursor cells [82]. Taken together, our data reinforce the idea that M-MDSCs could be a good tool to predict the improvement of clinical parameters related to neuroprotection and/or neuroreparative enhancement, which requires further experimental study.

Conclusions

Our data strongly suggest that the percentage of circulating M-MDSCs seems to be a good parameter to identify patients with a higher probability of responding suboptimally to fingolimod treatment. This observation paves the way for the existence of good biomarkers for monitoring or predicting effective response to this or other DMTs in the same family (ponesimod, siponimod, ozanimod), which will facilitate their more accurately informed recommendation for patient management in the near future.

Acknowledgements

The authors would like to thank Dr Virginia Vila-del Sol and Ángela Marquina Rodríguez at the Flow Cytometry Core Facility of the Hospital Nacional de Parapléjicos for their assistance with the confocal imaging and histological quantifications. Fingolimod was kindly supplied by Novartis Pharma AG under a signed Material Transfer Agreement.

Additional file 1: Table S1. List of antibodies used for flow cytometry and histology.

Additional file 2: Table S2. Demographic data from the fingolimod patients included in the study.

Additional file 3: Table S3. Correlations between M-MDSCs and clinical parameters after 12 months of fingolimod treatment.

Abbreviations

AUC: Area under the curve; CDP: Confirmed disability progression; CFA: Complete Freund’s adjuvant; CI: Confidence interval; CNS: Central nervous system; DMSC: Dimethylsulfoxide; DMTs: Disease-modifying treatments; dpo: Day post-onset; EAE: Experimental autoimmune encephalomyelitis; EAE-FTY: Fingolimod administered mice; EAE-Veh: Vehicle administered EAE mice; EC: Eriochrome cyanine; EDSS: Expanded Disability Status Scale; FBS: Fetal bovine serum; FTY720: Fingolimod; GA: Glatiramer acetate; Gd: Gadolinium; GTR: Good therapeutic response; HZ: Hazard ratio; IFN-β: Interferon-beta; IQR: Interquartile range; iv: Intravenously; l-Glu: l-Glutamine; MDS: Myeloid-derived suppressor cells; M-MDSCs: Monocytic-myeloid-derived suppressor cells; MNCs: Mononuclear cells; MOG: Myelin oligodendrocyte glycoprotein; MRI: Magnetic resonance imaging; MS: Multiple sclerosis; NDS: Normal donkey serum; NEDA-3: Non-evidence of disease activity-3; NR-MS: Non-responder MS patients that did not meet 2 or more of the NEDA-3 criteria after 12 months of treatment; NR-MSNEDA-3: Non-responder MS patients who did not meet all the NEDA-3 criteria after 12 months of treatment; Ntz: Natalizumab; P/S: Penicillin/streptomycin; PBMCs: Peripheral blood mononuclear cells; PBS: Sterile 1x phosphate buffered saline; PFA: Paraformaldehyde; PMN-MDSCs: Polymorphonuclear-myeloid-derived suppressor cells; R-MS: Responder MS patients who MS patients met 2 or more of the NEDA-3 criteria after 12 months of treatment; R-MSPCB1: Responder MS patients with no new relapses and no CDP after 12 months of treatment; R-MSCP2: Non-responder MS patients who either relapses and/or CDP after 12 months of treatment; R-MSCP12: Responder MS patients who met all the NEDA-3 criteria after 12 months of treatment; RR-MS: Relapsing–remitting multiple sclerosis; RT: Room temperature; S1PR: Sphingosine-1-phosphate receptor; SMI-32: Non-phosphorylated form of the neurofilament protein.
Funding
This work was supported by the Instituto de Salud Carlos III (PI18/00357, RD16-0015/0019, P121/00302, all co-funded by the European Union), the Fundación Merck Salud (FMS_2020_MS), Esclerosis Múltiple España (REEM-ESE-SS and REEM-EME_2018), ADEMTO, ATORDEM and AELEM. CC-T holds a predoctoral fellowship from the Instituto de Salud Carlos III (F119/00132, co-funded by the European Union). LC and JG-A were hired under PI18/00357 and RD16/0015/0019, respectively. DC, MCO and IM-D were hired by SESCAM.

Availability of data and materials
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
All the animal manipulations were approved by the institutional ethical committee (Comité Ético de Experimentación Animal del Hospital Nacional de Parapléjicos), and all the experiments were performed in compliance with the European guidelines for animal research (EC Council Directive 2010/63/EU, 90/219/EEC, Regulation No. 1946/2005), and with the Spanish National and Regional Guidelines for Animal Experimentation (RD 53/2013 and 178/2004, Ley 32/2007 and 9/2003, Decreto 320/2010). The study with human samples was approved by the corresponding local ethics committees of the Ramón y Cajal hospital, Valle d’Hebron Hospital and Donostia Hospital, and informed written consent was obtained from all the participants in accordance with the Helsinki declaration.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing financial interests.

Author details
1 Neuroimmuno-Repair Group, Hospital Nacional de Parapléjicos-SESCAM, Finca La Peralada s/n, 45017 Toledo, Spain. 2 Multiple Sclerosis Unit, Biodonostia Health Institute, 20014 Donostia-San Sebastián, Spain. 3 Neurology Department, Hospital Universitario Donostia, San Sebastián, Spain. 4 Immunology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCS), Madrid, Spain. 5 Multiple Sclerosis Unit, Neurology, Ramón y Cajal University Hospital, Madrid, Spain. 6 Neurology-Neuroimmunology Service, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d’Hebron, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. 7 Multiple Sclerosis Unit, Department of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Received: 24 August 2022   Accepted: 30 October 2022
Published online: 19 November 2022

References
1. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J. 2020;26(14):1816–21. https://doi.org/10.1177/1352458520970841.
2. Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380–90. https://doi.org/10.1016/j.amjmed.2020.05.049.
3. Liu Z, Liao Q, Wen H, Zhang Y. Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16(6):658–65. https://doi.org/10.1016/j.autrev.2017.04.010.
4. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777–88. https://doi.org/10.1212/WNL.0000000000005347.
5. Callegari I, Derfuss T, Galli E. Update on treatment in multiple sclerosis. La Presse Médicale. 2021;50(2):104068. https://doi.org/10.1016/j.lpm.2021.104068.
6. Chalmers TA, Kalinck T, Laurien B, Soensens PS, Magyari M, Sellebjerg F, et al. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. J Neurol. 2019;266:306–15. https://doi.org/10.1007/s00415-018-9126-y.
7. Merkle B, Butzkueven H, Traboulse AL, Havrdova E, Kalinck T. Timing of high-efﬁcacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16(6):658–65. https://doi.org/10.1016/j.autrev.2017.04.010.
8. Mehling M, Kappos L, Derfuss T. Fingolimod for multiple sclerosis: mechanisms of action, clinical outcomes, and future directions. Curr Neurol Neurosci Rep. 2011;11:492–7. https://doi.org/10.1007/s11910-011-0216-9.
9. Bascuñana P, Mõhle L, Brackhan M, Pahnke J. Fingolimod as a treatment in neurologic disorders beyond multiple sclerosis. Drugs R D. 2020;20:197–207. https://doi.org/10.1007/s40264-020-00316-1.
10. Antel J. Mechanisms of action of fingolimod in multiple sclerosis. Clin Exp Neuroimmunol. 2014;5(1):49–54. https://doi.org/10.1111/cen1.2079.
11. Sáenz-Cuesta M, Alberro A, Muñoz-Culla M, Osorio-Quejreta I, Fernandez-Mercado M, Lopeque J, et al. The first dose of fingolimod affects circulating extracellular vesicles in multiple sclerosis patients. Int J Mol Sci. 2018;19(8):2448. https://doi.org/10.3390/ijms19082448.
12. Kuhl J, Diisanio G, Dolson R, Aulittori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. 2015;21(8):1013–24. https://doi.org/10.1177/1352458514568827.
13. Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):131–9. https://doi.org/10.1001/jamaneurol.2014.3065.
14. Teniente-Serra A, Hervás JV, Quirant-Sánchez B, Mansilla MJ, Grau-López L, Ramo-Tello C, et al. Baseline differences in minor lymphocyte subpopulations may predict response to fingolimod in relapsing-remitting multiple sclerosis patients. CNS Neurosci Ther. 2016;22(7):584–92. https://doi.org/10.1111/cns.12548.
15. Quirant-Sánchez B, Hervás-García JV, Teniente-Serra A, Brieva L, Moral-Torres E, Cano A, et al. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients. CNS Neurosci Ther. 2018;24(12):1175–84. https://doi.org/10.1111/cns.12851.
16. Quirant-Sánchez B, Presas-Rodriguez S, Mansilla MJ, Teniente-Serra A, Hervás-García JV, Brieva L, et al. Th1/Th17/Th17/Th17 CMI lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment. Mediat Inflamm. 2019. https://doi.org/10.1155/2019/8147803.
17. Moreno-Torres I, González-García C, Marconi M, García-Grande A, Rodríguez-Esparzagoza L, Elvira V, et al. Immunophenotype and transcriptome profile of patients with multiple sclerosis treated with fingolimod: setting up a model for prediction of response in a 2-year translational study. Front Immunol. 2018. https://doi.org/10.3389/fimmu.2018.001693.
18. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7(1):12150. https://doi.org/10.1038/ncomms12150.
19. Millrud CR, Bengenfeldt C, Leeranderson K. On the origin of myeloid-derived suppressor cells. Oncotarget. 2017;8(20):3649–65. https://doi.org/10.18632/oncotarget.12278.
20. Veglia F, Sansierve E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485–98. https://doi.org/10.1038/s41577-020-00490-y.
21. Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, Kuchoo VK, et al. CD11b+ Ly6C+ suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol. 2007;179(8):5228–37. https://doi.org/10.4049/jimmunol.179.8.5228.
22. Mishra MK, Wang J, Silva C, Mack M, Yong VW. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol. 2012;181(2):642–51. https://doi.org/10.1016/j.ajpath.2012.05.011.
23. Moliné-Velázquez V, Ortega MC, Vila del Sol V, Melero-Jerez C, de Castro F, Clemente D. The synthetic retinoid Am 80 delays recovery in a model of multiple sclerosis by modulating myeloid-derived suppressor cell fate.
and viability. Neurobiol Dis. 2014;67:149–64. https://doi.org/10.1016/j.
neurobdis.2014.03.017.
24. Melero-Jerez C, Alonso-Gómez A, Mohivs E, Lebrón-Galán R, Machín-
Díaz I, de Castro F, et al. The proportion of myeloid-derived suppressor cells in
the spleen is related to the severity of the clinical course and
organ damage extent in a murine model of multiple sclerosis. Neurobiol
Dis. 2020;140:104869. https://doi.org/10.1016/j.neurobdis.2020.104869.
25. Liu G, Bi Y, Wang R, Yang H, Zhang Y, Wang X, et al. Targeting S1P1
receptor protects against murine immunological hepatic injury through
myeloid-derived suppressor cells. J Immunol. 2014;192(7):3068–79. 
https://doi.org/10.4049/jimmunol.1303801.
26. Li Y, Zhou T, Wang Y, Ning C, Lv Z, Han G, et al. The protumorigenic poten-
tial of FTYY70 by promoting extracellular hemomodosis and MDSC
accumulation. Oncogene. 2017;36:760–71. https://doi.org/10.1038/onc.
2017.2.
27. Asakura T, Ishii M, Namkoong H, Suzuki S, Kagawa S, Yagi K, et al.
Phosphoglucone 1-phosphate receptor modulator ONO-4641 stimulates
CD11b+Gr-1+ cell expansion and inhibits lymphocyte infiltration in the
lungs to ameliorate murine pulmonary emphysema. Mucosal Immunol.
2018;11:1606–20. https://doi.org/10.1038/s41385-018-0077-7.
28. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Felder
K, et al. FTYY70 ameliorates murine sclerosedermatosus chronic graft-
versus-host disease by promoting expansion of splenic regulatory cells
and inhibiting immune cell infiltration into skin. Arthritis Rheum.
2013;65(6):1624–35. https://doi.org/10.1002/art.37933.
29. Vegla F, Perego M, Gabrilovich D. Myeloid-suppressor cells coming
of age review-article. Nat Immunol. 2018;19:108–19. https://doi.
org/10.1038/s41590-017-0022-x.
30. Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, et al.
Critical role of granulocytic myeloid-suppressor cells in the
regulation of central nervous system autoimmunity disease. J Immunol.
2012;192(3):1334. https://doi.org/10.4049/jimmunol.1390073.
31. Iacobaeus E, Douagi I, Jitschin R, Marcussen-Ståhl M, Andrén AT, Gavín C,
et al. Phenotypic and functional alterations of myeloid-suppressor
cells during the disease course of multiple sclerosis. Immunol Cell
Biol. 2018;96(6):820–30. https://doi.org/10.1111/imcb.12042.
32. Cantoni C, Cagnarella F, Ghezzi L, Mikisell B, Bollman B, Berrien-Elliot MW,
et al. MIR-223 regulates the number and function of myeloid-suppressed
suppressor cells in multiple sclerosis and experimental autoimmune
encephalomyelitis. Acta Neuropathol. 2017;133:61–77. https://doi.
org/10.1007/s00401-016-1621-6.
33. Webb M, Tham CS, Lin FF, Lanosa-Willingham K, Yu N, Hale J, et al.
Phosphoglucone 1-phosphate receptor agonist attenuates relapsing-remitting
experimental autoimmune encephalitis in SJL mice. J Neuroimmunol.
2004;153(1–2):108–21. https://doi.org/10.1016/j.jneuroim.2004.04.015.
34. Colombo E, Di Dario M, Capitolo E, Chaabane L, Newcombe J, Martino G,
et al. Fingolimod may support neuroprotection via blockade of astrocyte
suppressor cells in multiple sclerosis and experimental autoimmune
encephalomyelitis by inducing myeloid-derived suppressor cells. J Immunol.
2013;191(7):764–77. https://doi.org/10.4049/jimmunol.1202556.
35. Sempere AP, Martin-Medina P, Berenguer-Ruiz L, Pérez-Carmona N,
Sanchez-Perez R, Polache-Vengud J, et al. Switching from natalizumab to
fingolimod: an observational study. Acta Neurol Scand. 2013. https:
doi.org/10.1111/ane.12082.
36. Cohen M, Maillard E, Tourbah A, De Seze J, Vukusic S, Brasset D, et al.
Switching from natalizumab to fingolimod in multiple sclerosis. JAMA.
Neurol. 2014;71(4):436–41. https://doi.org/10.1001/jamaneurol.2013. 
6240.
37. Butzkueven H, Giacomini PS, Cohan S, Ziemssen T, Sienkiewcz D, Zhang
Y, et al. Safety of fingolimod in patients with multiple sclerosis switched
from natalizumab: results from TRANSITION-A 2-year, multicenter, obser-
vation-cohort study. Brain Sci. 2022;12(2):215. https://doi.org/10.3390/
brainsci12020215.
38. Liu G, Nos C, Tintore M, Tilleux N, Galán I, Pelayo R, et al. Defining the
response to interferon-β in relapsing-remitting multiple sclerosis patients.
Ann Neurol. 2006;59:344–52. https://doi.org/10.1002/ana.20740.
39. Gasperini C, Prosperini L, Tintore M, Sormani MP, Filippi M, Rio J, et al.
Unraveling treatment response in multiple sclerosis: a clinical and MRI
challenge. Neurology. 2019;92(4):180–92. https://doi.org/10.1212/WNL.
0000000000006910.
40. Wiendl H, Gold R, Berger T, Derflus T, Linker R, Maurer M, et al. Multiple
Sclerosis Therapy Consensus Group (MSTCG): position statement on
disease-modifying therapies for multiple sclerosis (white paper). Ther Adv
Neurodis. 2021. https://doi.org/10.1177/17562864211039468.
41. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Ridelus-Corr R,
Kasper LH. Repeated subcutaneous injections of IL-12/23 p40 neutralis-
ting antibody, ustekinumab, in patients with relapsing-remitting multiple
sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-
-ranging study. Lancet Neurol. 2008;7(9):796–804. https://doi.org/10.
1016/S1474-4422(08)70173-X.
42. Hartung HP, Kieseier BC. Atacicept: targeting B cells in multiple sclerosis.
Ther Adv Neurol Disord. 2010;3(4):205–16. https://doi.org/10.1177/ 
17562864100000000920.
43. Steimann L, Zumwalt H. So successfully to apply animal studies in
experimental allergic encephalomyelitis to research on multiple sclerosis.
Ann Neurol. 2006;60(1):12–21. https://doi.org/10.1002/ana.20913.
44. T’Hart BA, Jagessar SA, Kap YS, Haanstra KG, Philippens I-HCHM, Serguson
C, et al. Improvement of preclinical animal models for autoimmune-
mediated disorders via reverse translation of failed therapies. Drug Discov
Today. 2014;19(9):1394–401. https://doi.org/10.1016/j.drudis.2014.03.023.
45. Rossi S, Lo Giudice T, De Chiara V, Mussella A, Studer V, Motta C, et al.
Oral fingolimod rescues the functional deficits of synapses in experimental
autoimmune encephalomyelitis. Br J Pharmacol. 2012;165(4):861–9. 
https://doi.org/10.1111/j.1476-5381.2011.01579.x.
46. Tsai H-C, Huang Y, Garris CS, Moreno MA, Griffin CW, Han MH. Effects of
sphingosine-1-phosphate receptor 1 phosphorylation in response to
FTTY70 during neuroinflammation. JCI Insight. 2016;1(9):e86462. https://
doi.org/10.1172/jci.insight.86462.
47. Kyran EL, Robinson C, Kocovski P, Li Z, Dang PT, Hale MW, et al. Multiple
pathological mechanisms contribute to hippocampal damage in the
experimental autoimmune encephalomyelitis model of multiple sclero-
sis. NeuroReport. 2018;29(1):19–24. https://doi.org/10.1093/ 
neuroreport/nyx0000000000920.
48. Mangano K, Nicoletti A, Patti F, Donia M, Malaguarnera L, Signorelli S, et al.
Variable effects of cyclophosphamide in rodent models of experimen-
tal allergic encephalomyelitis. NeuroReport. 2018;29(6):658–61. https:
doi.org/10.1093/ 
neuroreport/nyx0000000000920.
49. Wille PE, Reinherz S, Kuhn S, Pedrettiuna X, Petrukkovski L, Faisannt S,
et al. Laquinimod protects the optic nerve and retina in an experimental
autoimmune encephalomyelitis model. J Neuroinflamm. 2018;15(1):183. https://doi.org/10.1186/s12974-018-1208-3.

59. Yang T, Zha Z, Yang X, Kang YZ, Wang X, Tong Y, et al. Neurprotective effects of fingolimod supplement on the retina and optic nerve in the mouse model of experimental autoimmune encephalomyelitis. Front. Neurosci. 2021;15:663541. https://doi.org/10.3389/fnins.2021.663541.

60. Benson CA, Wong G, Tenorio G, Baker GB, Kerr BJ. The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE). Behav Brain Res. 2013;252:302–11. https://doi.org/10.1016/j.bbr.2013.06.019.

61. Martín-Álvarez R, Paúl-Fernández N, Palomo V, Gil C, Martínez A, Mengod G. A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. J Chem Neuroanat. 2017;80:27–36. https://doi.org/10.1002/jnr.24509.

62. Yazdi A, Ghasemi-Kasman M, Javan M. Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: an overview on remyelination process. J Neurosci Res. 2020;98(3):524–36. https://doi.org/10.1002/jnr.25409.

63. Jm P, Sz I. Importance of the non-responder in deciphering animal behavior of experimental autoimmune encephalomyelitis. J Mult Scler. 2016;3:1002/ jnr. 24509.

64. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon β response status in multiple sclerosis patients. Ann Neurrol. 2004;56(4):548–55. https://doi.org/10.1002/ana.2224.

65. Rio C, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. 2009;5(10):533–60. https://doi.org/10.1038/nrneuro.2009.139.

66. Ian S, Zagon LAH. Low dose naltrexone treatment of established relapsing-remitting experimental autoimmune encephalomyelitis. J Mult Scler. 2015;2:136. https://doi.org/10.14172/2376-0389.1000136.

67. Hammer LA, Zagon IS, McLaughlin PJ. Improved clinical behavior of established relapsing-remitting experimental autoimmune encephalomyelitis following treatment with endogenous opioids: implications for the treatment of multiple sclerosis. Brain Res Bull. 2015;112:42–51. https://doi.org/10.1016/j.brainresbull.2015.01.009.

68. Manouchehri N, Zhang Y, Salter A, Hussain RZ, Hartung HP, Hemmer B, et al. Clinical trials in multiple sclerosis: potential future trial designs. Ther Adv Neurol Disord. 2019;12:175628641987095. https://doi.org/10.1177/175628641987095.

69. Mecha M, Felui A, Machin I, Cordero C, Camillo-Salinas F, Mestre L, et al. 2-AG limits Th11er’s virus induced acute neuroinflammation by modulating microglia and promoting MDSCs. Glia. 2018;66(7):147–63. https://doi.org/10.1002/glia.23317.

70. Melero-Jerez C, Suárez-Maiz M, Lebrón-Galán R, Martin-Barbasco C, Oliver-Martos B, Machín-Díaz I, et al. The presence and suppressive activity of myeloid-derived suppressor cells are potentiated after interferon-β treatment in a murine model of multiple sclerosis. Neurol Biol Dis. 2019;127:13–31. https://doi.org/10.1016/j.nbd.2019.02.014.

71. Wang Z, Zheng G, Li G, Wang M, Ma Z, Li H, et al. Methylprednisolone alleviates multiple sclerosis by expanding myeloid-derived suppressor cells via glucocorticoid receptor β and S100A8/9 up-regulation. J Cell Mol Med. 2020;24(23):13703–14. https://doi.org/10.1111/jcmm.15928.

72. Chung J-S, Tamura K, Akiyoshi H, Cruz PD, Ariizumi K. The DC-HIL/syn-1/-mediated macrophage polarization modulates microglial polarization in a murine model of multiple sclerosis. Adv Neurol Disord. 2019;12:1756286419847095. https://doi.org/10.1177/1756286419847095.

73. King IL, Dickendesher TL, Segal BM. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood. 2009;113(14):3190–7. https://doi.org/10.1182/blood-2008-07-168575.

74. Mildner A, Mack M, Schmidt H, Brück W, Djukic M, Zabel MD, et al.CCR2+Ly-6C+ monocytes are crucial for the effector phase of autoimmune in the central nervous system. Brain. 2009;132(Pt 9):2487–500. https://doi.org/10.1038/brainawp.2009.132.

75. Giles DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, Purushotham P, Pitt D, et al. Myeloid cell plasticity in the evolution of central nervous system autoimmunity. Ann Neurol. 2018;83(1):131–41. https://doi.org/10.1002/ana.25128.